|
Sino Biopharmaceutical Limited, a leading innovation and research and development (R&D)-driven pharmaceutical group in China, announced that Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a subsidiary of the company, has entered into an exclusive license agreement with AstraZeneca for the development, manufacturing and commercialization of the Group’s PDE3/4 inhibitor, TQC3721.
Subject to the terms and conditions of the Agreement, the Group shall grant AstraZeneca an exclusive license to develop, manufacture and commercialize TQC3721 outside China. AstraZeneca also gains exclusive global rights for certain future development programmes. The Group is eligible to receive an upfront payment of US 200 million, with additional development, regulatory and sales milestones, totalling up to USD$1.9 billion, as well as tiered royalties ranging up to double-digit percentages based on the annual net sales of TQC3721 products. The Agreement is subject to customary closing conditions, including regulatory clearances.
As a global leader in respiratory medicine, this partnership will leverage AstraZeneca’s deep clinical development experience and respiratory expertise with the Group’s innovation capabilities, accelerating the global clinical development of TQC3721, maximizing the potential clinical and commercial value of this potential best-in-class medicine to benefit more patients worldwide.
This partnership represents the Group’s second out-licensing transaction with a multinational pharmaceutical company this year, following the licensing collaboration with Sanofi in February. It marks another important milestone in the Group’s globalization journey and further validates the Group’s in-house innovation capabilities and outstanding business development execution. Looking ahead, the Group will continue to expand its global partner network, deepen diversified strategic collaborations with multinational pharmaceutical companies, and strive to become the preferred innovation partner for global pharmaceutical companies.
TQC3721 is a highly differentiated inhaled PDE3/4 inhibitor discovered and developed by the Group, with potential best-in-class characteristics across multiple respiratory indications. Through balanced inhibition of both PDE3 and PDE4, TQC3721 is designed to deliver synergistic bronchodilatory and anti-inflammatory effects, with the potential to improve lung function, reduce exacerbations and address broader disease burden in patients with chronic respiratory diseases.
TQC3721 is being developed in China by the Group across nebulized and dry powder inhaler (“DPI”) formulations, supporting use across different patient segments, disease severities and commercial settings. In chronic obstructive pulmonary disease (“COPD”), TQC3721 in a nebulized formulation has generated phase IIb data that demonstrate a potential best-in-class profile study. The nebulized formulation is currently being evaluated in a phase III clinical trial in China, while the dry powder inhaler formulation is also being advanced in a Phase II clinical trial. TQC3721 has the potential to become the first domestically developed inhaled dual PDE3/4 inhibitor approved in China.
Sino Biopharmaceutical Limited is the pharmaceutical sector of Thailand's Charoen Pokphand Group in China. It is a leading innovation and research and development (R&D)-driven pharmaceutical group in China, with business covering the entire industry chain of R&D, manufacturing, and commercialization of innovative drugs, biological products, and high-end generic drugs.
|